N
RLMD icon

Nuveen’s Relmada Therapeutics RLMD Stock Holding History

Nuveen’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-77,379
Closed -$175K – 3279
2023
Q1 		$175K Sell
77,379
-2,779
-3% -$9.58K ﹤0.01% 3005
2022
Q4 		$280K Sell
80,158
-5,951
-7% -$52.3K ﹤0.01% 3000
2022
Q3 		$3.19M Sell
86,109
-672
-0.8% -$18.6K ﹤0.01% 2148
2022
Q2 		$1.65M Buy
86,781
+15,782
+22% +$344K ﹤0.01% 2536
2022
Q1 		$1.62M Buy
70,999
+12,333
+21% +$255K ﹤0.01% 2606
2021
Q4 		$1.32M Sell
58,666
-2,049
-3% -$45.6K ﹤0.01% 2749
2021
Q3 		$1.59M Buy
60,715
+2,427
+4% +$65K ﹤0.01% 2783
2021
Q2 		$1.87M Sell
58,288
-3,583
-6% -$124K ﹤0.01% 2748
2021
Q1 		$2.18M Buy
61,871
+2,469
+4% +$86.4K ﹤0.01% 2577
2020
Q4 		$1.91M Buy
59,402
+5,638
+10% +$194K ﹤0.01% 2538
2020
Q3 		$2.02M Sell
53,764
-3,520
-6% -$136K ﹤0.01% 2382
2020
Q2 		$2.56M Buy
+57,284
New +$2.42M ﹤0.01% 2231

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Nuveen's RLMD Position: Q2 2023 in Review

Nuveen sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 77,379 shares — an estimated $175K sold.

Nuveen first reported a position in RLMD in Q2 2020 and held it in 12 quarters. The position peaked at $3.19M in Q3 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

  • Nuveen reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Nuveen sold 77,379 Relmada Therapeutics shares in Q2 2023, an estimated $175K.
  • Nuveen first reported a position in Relmada Therapeutics in Q2 2020 and held it in 12 quarters.
  • Nuveen's Relmada Therapeutics position peaked at $3.19M in Q3 2022.
  • 95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.